Connect Biopharma's 2025 10-K Reveals Near-Zero Revenue, Widened $(1.00) EPS Loss
CNTB has more than doubled off its 52-week low of $0.51 on elevated volume (2.7× avg).
Summary
Connect Biopharma reported its 2025 10-K results, revealing a sharp decline in license and collaboration revenue to $0.06 million from $26.03 million in 2024, and a widened net loss of $(1.00) per share. This financial update provides a crucial operational context following the company's recent announcement of a $20.2 million private placement and highly positive Phase 3 results for its drug candidate, Rademikibart. The significant revenue drop and increased losses underscore the company's substantial cash burn and reliance on external financing, despite clinical advancements. Traders will be evaluating the company's liquidity and its path to commercialization to offset these operational losses.
At the time of this announcement, CNTB was trading at $2.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.5M. The 52-week trading range was $0.51 to $3.82. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.